Chronic hepatitis C infection is one of the most important causes of cirrhosis and hepatocellular carcinoma in Thailand and worldwide. Hepatitis C virus causes liver inflammation and fibrosis, and may involve other systems such as the kidney and hematological system. The combination of Pegylated interferon and ribavirin is the current standard treatment for chronic hepatitis C infection in Thailand. The treatment has significant side effects, a long duration of treatment, is contraindicated in poor liver function and needs frequent monitoring. The new direct-acting antiviral (DAA) treatment, with and without interferon and ribavirin, produces results in higher response rates, shorter treatment duration and less side effects. These will lead to the new era of hepatitis C treatment and eradication.
chronic hepatitis C, extrahepatic manifestation